CD96 as a Therapeutic Target for CAR T Cell Therapy in Acute Myeloid Leukemia

Researchers developed a panel of CD96-CAR T cells using single-chain variable fragments derived from various monoclonal antibodies, incorporating distinct transmembrane and costimulatory domains.